Your browser doesn't support javascript.
loading
Genetic toxicology in silico protocol.
Hasselgren, Catrin; Ahlberg, Ernst; Akahori, Yumi; Amberg, Alexander; Anger, Lennart T; Atienzar, Franck; Auerbach, Scott; Beilke, Lisa; Bellion, Phillip; Benigni, Romualdo; Bercu, Joel; Booth, Ewan D; Bower, Dave; Brigo, Alessandro; Cammerer, Zoryana; Cronin, Mark T D; Crooks, Ian; Cross, Kevin P; Custer, Laura; Dobo, Krista; Doktorova, Tatyana; Faulkner, David; Ford, Kevin A; Fortin, Marie C; Frericks, Markus; Gad-McDonald, Samantha E; Gellatly, Nichola; Gerets, Helga; Gervais, Véronique; Glowienke, Susanne; Van Gompel, Jacky; Harvey, James S; Hillegass, Jedd; Honma, Masamitsu; Hsieh, Jui-Hua; Hsu, Chia-Wen; Barton-Maclaren, Tara S; Johnson, Candice; Jolly, Robert; Jones, David; Kemper, Ray; Kenyon, Michelle O; Kruhlak, Naomi L; Kulkarni, Sunil A; Kümmerer, Klaus; Leavitt, Penny; Masten, Scott; Miller, Scott; Moudgal, Chandrika; Muster, Wolfgang.
Affiliation
  • Hasselgren C; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. Electronic address: hasselgren.catrin@gene.com.
  • Ahlberg E; Predictive Compound ADME & Safety, Drug Safety & Metabolism, AstraZeneca IMED Biotech Unit, Mölndal, Sweden.
  • Akahori Y; Chemicals Evaluation and Research Institute, 1-4-25 Kouraku, Bunkyo-ku, Tokyo, 112-0004, Japan.
  • Amberg A; Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Hoechst, D-65926, Frankfurt am Main, Germany.
  • Anger LT; Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Hoechst, D-65926, Frankfurt am Main, Germany.
  • Atienzar F; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.
  • Auerbach S; The National Institute of Environmental Health Sciences, Division of the National Toxicology Program, Research Triangle Park, NC, 27709, USA.
  • Beilke L; Toxicology Solutions Inc., San Diego, CA, USA.
  • Bellion P; DSM Nutritional Products, Kaiseraugst, Switzerland.
  • Benigni R; Alpha-PreTox, via G.Pascoli 1, 00184, Roma, Italy.
  • Bercu J; Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA.
  • Booth ED; Syngenta, Product Safety Department, Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6EY, UK.
  • Bower D; Leadscope, Inc, 1393 Dublin Rd, Columbus, OH, 43215, USA.
  • Brigo A; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Cammerer Z; Janssen Research & Development, 1400 McKean Road, Spring House, PA, 19477, USA.
  • Cronin MTD; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK.
  • Crooks I; British American Tobacco, Research and Development, Regents Park Road, Southampton, Hampshire, SO15 8TL, UK.
  • Cross KP; Leadscope, Inc, 1393 Dublin Rd, Columbus, OH, 43215, USA.
  • Custer L; Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ, 08903, USA.
  • Dobo K; Pfizer Global Research & Development, 558 Eastern Point Road, Groton, CT, 06340, USA.
  • Doktorova T; Douglas Connect GmbH, Technology Park Basel, Hochbergerstrasse 60C, CH-4057, Basel / Basel-Stadt, Switzerland.
  • Faulkner D; Lawrence Berkeley National Laboratory, One Cyclotron Road, MS 70A-1161A, Berkeley, CA, 947020, USA.
  • Ford KA; Global Blood Therapeutics, 171 Oyster Point Boulevard, South San Francisco, CA, 94080, USA.
  • Fortin MC; Jazz Pharmaceuticals, Inc., 200 Princeton South Corporate Center, Suite 180, Ewing, NJ, 08628, USA; Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, 170 Frelinghuysen Rd, Piscataway, NJ, 08855, USA.
  • Frericks M; BASF SE, 67056, Ludwigshafen, Germany.
  • Gad-McDonald SE; Gad Consulting Services, 4008 Barrett Drive, Suite 201, Raleigh, NC, 27609, USA.
  • Gellatly N; National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, UK.
  • Gerets H; UCB BioPharma SPRL, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.
  • Gervais V; Servier Group, 905 route de Saran, 45520, Gidy, France.
  • Glowienke S; Novartis Pharma AG, Pre-Clinical Safety, Werk Klybeck, CH, 4057, Basel, Switzerland.
  • Van Gompel J; Janssen Pharmaceutical Companies of Johnson & Johnson, 2340, Beerse, Belgium.
  • Harvey JS; GlaxoSmithKline Pre-Clinical Development, Park Road, Ware, Hertfordshire, SG12 0DP, UK.
  • Hillegass J; Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ, 08903, USA.
  • Honma M; Division of Genetics and Mutagenesis, National Institute of Health Sciences, Kanagawa, 210-9501, Japan.
  • Hsieh JH; Kelly Government Solutions, Research Triangle Park, NC, 27709, USA.
  • Hsu CW; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Barton-Maclaren TS; Existing Substances Risk Assessment Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.
  • Johnson C; Leadscope, Inc, 1393 Dublin Rd, Columbus, OH, 43215, USA.
  • Jolly R; Toxicology Division, Eli Lilly and Company, Indianapolis, IN, USA.
  • Jones D; Medicines and Healthcare Products Regulatory Agency, 10 South Colonnade, Canary Wharf, London, E14 4PU, UK.
  • Kemper R; Vertex Pharmaceuticals Inc., Predictive and Investigative Safety Assessment, 50 Northern Ave, Boston, MA, USA.
  • Kenyon MO; Pfizer Global Research & Development, 558 Eastern Point Road, Groton, CT, 06340, USA.
  • Kruhlak NL; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Kulkarni SA; Existing Substances Risk Assessment Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.
  • Kümmerer K; Institute for Sustainable and Environmental Chemistry, Leuphana University Lüneburg, Scharnhorststraße 1/C13.311b, 21335, Lüneburg, Germany.
  • Leavitt P; Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ, 08903, USA.
  • Masten S; The National Institute of Environmental Health Sciences, Division of the National Toxicology Program, Research Triangle Park, NC, 27709, USA.
  • Miller S; Leadscope, Inc, 1393 Dublin Rd, Columbus, OH, 43215, USA.
  • Moudgal C; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
  • Muster W; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
Regul Toxicol Pharmacol ; 107: 104403, 2019 Oct.
Article in En | MEDLINE | ID: mdl-31195068
ABSTRACT
In silico toxicology (IST) approaches to rapidly assess chemical hazard, and usage of such methods is increasing in all applications but especially for regulatory submissions, such as for assessing chemicals under REACH as well as the ICH M7 guideline for drug impurities. There are a number of obstacles to performing an IST assessment, including uncertainty in how such an assessment and associated expert review should be performed or what is fit for purpose, as well as a lack of confidence that the results will be accepted by colleagues, collaborators and regulatory authorities. To address this, a project to develop a series of IST protocols for different hazard endpoints has been initiated and this paper describes the genetic toxicity in silico (GIST) protocol. The protocol outlines a hazard assessment framework including key effects/mechanisms and their relationships to endpoints such as gene mutation and clastogenicity. IST models and data are reviewed that support the assessment of these effects/mechanisms along with defined approaches for combining the information and evaluating the confidence in the assessment. This protocol has been developed through a consortium of toxicologists, computational scientists, and regulatory scientists across several industries to support the implementation and acceptance of in silico approaches.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Toxicology / Models, Theoretical / Mutagens Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Regul Toxicol Pharmacol Year: 2019 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Toxicology / Models, Theoretical / Mutagens Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Regul Toxicol Pharmacol Year: 2019 Document type: Article